Peripheral blood biomarkers associated with toxicity and treatment characteristics after 131I-metaiodobenzylguanidine therapy in patients with neuroblastoma
K Campbell, EE Karski, A Olow, DA Edmondson… - International Journal of …, 2017 - Elsevier
Purpose Few tools exist to predict clinical outcomes after radiopharmaceutical therapy. Our
goal was to identify associations between blood-based biomarkers of radiation effect and …
goal was to identify associations between blood-based biomarkers of radiation effect and …
Impact of Whole‐Body Radiation Dose on Response and Toxicity in Patients With Neuroblastoma After Therapy With 131I‐Metaiodobenzylguanidine (MIBG)
M Trieu, SG DuBois, E Pon, L Nardo… - Pediatric blood & …, 2016 - Wiley Online Library
Background 131I‐metaiodobenzylguanidine (131I‐MIBG) is a targeted radiopharmaceutical
for patients with neuroblastoma. Despite its tumor‐specific uptake, the treatment with 131I …
for patients with neuroblastoma. Despite its tumor‐specific uptake, the treatment with 131I …
Modulation of Radiation Biomarkers in a Randomized Phase II Study of 131I-MIBG With or Without Radiation Sensitizers for Relapsed or Refractory Neuroblastoma
K Campbell, S Groshen, AC Evans, S Wilson… - International Journal of …, 2023 - Elsevier
Purpose 131 I-metaiodobenzylguanidine (131 I-MIBG) has demonstrated efficacy as a
single agent in neuroblastoma. Recent trials have focused on 131 I-MIBG combination …
single agent in neuroblastoma. Recent trials have focused on 131 I-MIBG combination …
Peripheral blood transcript signatures after internal 131I-mIBG therapy in relapsed and refractory neuroblastoma patients identifies early and late biomarkers of …
AC Evans, T Setzkorn, DA Edmondson… - Radiation …, 2022 - meridian.allenpress.com
131I-metaiodobenzylguanidine (131I-mIBG) is a targeted radiation therapy developed for
the treatment of advanced neuroblastoma. We have previously shown that this patient cohort …
the treatment of advanced neuroblastoma. We have previously shown that this patient cohort …
Pediatric 131I-MIBG therapy for neuroblastoma: whole-body 131I-MIBG clearance, radiation doses to patients, family caregivers, medical staff, and radiation safety …
J Willegaignon, KP Crema, NC Oliveira… - Clinical nuclear …, 2018 - journals.lww.com
Purpose 131 I-metaiodobenzylguanidine (131 I-MIBG) has been used in the diagnosis and
therapy of neuroblastoma in adult and pediatric patients for many years. In this study, we …
therapy of neuroblastoma in adult and pediatric patients for many years. In this study, we …
Transcript Analysis for Internal Biodosimetry Using Peripheral Blood from Neuroblastoma Patients Treated with 131I-mIBG, a Targeted Radionuclide
DA Edmondson, EE Karski, A Kohlgruber… - Radiation …, 2016 - meridian.allenpress.com
Calculating internal dose from therapeutic radionuclides currently relies on estimates made
from multiple radiation exposure measurements, converted to absorbed dose in specific …
from multiple radiation exposure measurements, converted to absorbed dose in specific …
Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with 131I-MIBG
KK Matthay, C Panina, J Huberty, D Price… - Journal of Nuclear …, 2001 - Soc Nuclear Med
The purpose of our study was to determine the effect of tumor-targeted radiation in
neuroblastoma by correlating administered 131I-metaiodobenzylguanidine (MIBG) activity to …
neuroblastoma by correlating administered 131I-metaiodobenzylguanidine (MIBG) activity to …
Radiation exposure to family caregivers and nurses of pediatric neuroblastoma patients receiving 131I-metaiodobenzylguanidine (131I-MIBG) therapy
RJ Markelewicz Jr, WA Lorenzen… - Clinical nuclear …, 2013 - journals.lww.com
Purpose 131 I-MIBG provides molecularly targeted radiotherapy for pediatric neuroblastoma
patients with relapsed or refractory disease. At our institution, designated family caregivers …
patients with relapsed or refractory disease. At our institution, designated family caregivers …
Reaching the target dose with one single 131I‐mIBG administration in high‐risk neuroblastoma: The determinant impact of the primary tumour
F Fiz, A Cirone, S Righi, M Massollo… - Pediatric Blood & …, 2024 - Wiley Online Library
Abstract Background: 131I‐metaiodobenzylguanidine (131I‐mIBG) effectiveness in children
with metastasised neuroblastoma (NB) is linked to the effective dose absorbed by the target; …
with metastasised neuroblastoma (NB) is linked to the effective dose absorbed by the target; …
Time to resolution of iodine‐123 metaiodobenzylguanidine (123I‐MIBG) avidity and local control outcomes for high‐risk neuroblastoma following radiation therapy
J Oh, P Gutkin, YP Wang, N Sandhu… - Journal of Medical …, 2023 - Wiley Online Library
Introduction 123I‐MIBG scan is used in neuroblastoma (NB) to monitor treatment response.
Time to resolution of 123I‐MIBG avidity after radiation therapy (RT) is unknown. We sought …
Time to resolution of 123I‐MIBG avidity after radiation therapy (RT) is unknown. We sought …
相关搜索
- neuroblastoma patients 131i mibg
- blood biomarkers patients with neuroblastoma
- 131i metaiodobenzylguanidine toxicity in patients
- 131i metaiodobenzylguanidine blood biomarkers
- response and toxicity patients with neuroblastoma
- peripheral blood 131i mibg
- neuroblastoma patients radiation exposure
- radiation biomarkers 131i mibg
- metaiodobenzylguanidine mibg response and toxicity
- radiation dose toxicity in patients
- 131i metaiodobenzylguanidine radiation exposure
- neuroblastoma patients targeted radionuclide
- neuroblastoma patients transcript analysis
- neuroblastoma patients family caregivers
- peripheral blood targeted radionuclide
- peripheral blood transcript analysis